Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Jan 1.

Published in final edited form as: Nutr Cancer. 2021 Jan 12;74(1):110–121. doi: 10.1080/01635581.2020.1870706

TABLE 1.

Demographic and Baseline Data of Subjects in Tables 2 and 3

	Subjects in Table 2				Subjects in Table 3
	Testosterone		SHBG & Free Testosterone		Estradiol		VEGF		Fas/Fas Ligand & IGF-1 - IGFBP-3
	Soy	Placebo	Soy	Placebo	Soy	Placebo	Soy	Placebo	Soy	Placebo

Number of subjects	19	23	10	14	16	17	9	9	7	8
Age, years (mean) 95% CI	58.3 (55.7, 61.0)	61.0 (57.7, 64.3)	58.7 (54.4, 63.1)	61.1 (56.8, 65.5)	57.9 (55.1, 60.7)	60.1 (56.0, 64.1)	60.2 (54.9, 65.5)	61.8 (56.2, 67.4)	57.9 (52.4, 63.3)	59.3 (52.7, 65.8)
Body Weight, kg (mean) 95% CI	86.9 (79.9, 93.9)	93.4 (85.9, 100.9)	88.3 (78.6, 98.0)	97.4 (87.3, 108.1)	86.5 (78.7, 94.2)	93.5 (85.6, 101.4)	89.7 (82.0, 97.5)	92.3 (83.8, 100.9)	87.9 ^c (76.0, 100.0)	101.2 ^c (89.7, 112.6)
BMI (mean) n^a 95% CI	29.0 15 (24.7, 29.2)	28.6 19 (26.3, 31.0)	27.4 7 (24.6, 30.3)	30.3 11 (26.8, 33.8)	26.7 13 (24.1, 29.3)	28.5 13 (26.0, 31.1)	26.6 8 (22.5, 30.7)	26.2 8 (24.5, 27.9)	26.9 ^d 5 (22.4, 31.4)	32.1 ^d 5 (28.4, 35.9)
Race^b
White	18	22	10	13	15	17	9	8	7	8
African American	1	1	0	1	1	0	0	1	0	0

^a

BMI could not be calculated for some subjects because of missing height data.

^b

Self-reported.

^c

P = 0.077 for difference between the soy and placebo groups (2-sided t-test).

^d

P = 0.039 for difference between the soy and placebo groups (2-sided t-test).